Anti-HCV drugs in the pipeline
Several directly acting and host targeting antivirals that inhibit hepatitis C virus replication have entered clinical trials. Among the most advanced of these are RG7128, an inhibitor of the NS5B polymerase; BMS-790052, an inhibitor of NS5A; and alisporivir, an inhibitor of human cyclophilins. These agents have potent antiviral activity in chronic HCV patients, act additively or synergistically with inhibitors of the HCV NS3/4A protease, and improve the rate of virologic response produced by…
Volume 1, Issue 6, 01 December 2011, Pp 607-616
Yang, P.L. | Gao, M. | Lin, K. | Liu, Q. | Villareal, V.A.